Emergent Biosolutions EBITDA Margin 2010-2022 | EBS
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Emergent Biosolutions (EBS) over the last 10 years. The current EBITDA margin for Emergent Biosolutions as of March 31, 2022 is .
| Emergent Biosolutions EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2022-03-31 |
$1.76B |
$0.39B |
22.41% |
| 2021-12-31 |
$1.79B |
$0.48B |
26.83% |
| 2021-09-30 |
$1.65B |
$0.46B |
27.89% |
| 2021-06-30 |
$1.71B |
$0.55B |
32.36% |
| 2021-03-31 |
$1.71B |
$0.66B |
38.63% |
| 2020-12-31 |
$1.56B |
$0.55B |
35.41% |
| 2020-09-30 |
$1.33B |
$0.37B |
27.68% |
| 2020-06-30 |
$1.26B |
$0.38B |
29.92% |
| 2020-03-31 |
$1.11B |
$0.24B |
22.02% |
| 2019-12-31 |
$1.11B |
$0.23B |
20.52% |
| 2019-09-30 |
$1.02B |
$0.16B |
15.54% |
| 2019-06-30 |
$0.88B |
$0.09B |
10.58% |
| 2019-03-31 |
$0.86B |
$0.15B |
17.52% |
| 2018-12-31 |
$0.78B |
$0.15B |
19.54% |
| 2018-09-30 |
$0.71B |
$0.18B |
25.92% |
| 2018-06-30 |
$0.68B |
$0.21B |
30.40% |
| 2018-03-31 |
$0.56B |
$0.15B |
25.98% |
| 2017-12-31 |
$0.56B |
$0.17B |
29.95% |
| 2017-09-30 |
$0.52B |
$0.16B |
31.21% |
| 2017-06-30 |
$0.51B |
$0.15B |
29.24% |
| 2017-03-31 |
$0.50B |
$0.14B |
27.63% |
| 2016-12-31 |
$0.49B |
$0.14B |
29.45% |
| 2016-09-30 |
$0.48B |
$0.18B |
37.24% |
| 2016-06-30 |
$0.49B |
$0.20B |
41.38% |
| 2016-03-31 |
$0.53B |
$0.23B |
42.99% |
| 2015-12-31 |
$0.49B |
$0.18B |
36.20% |
| 2015-09-30 |
$0.45B |
$0.17B |
36.89% |
| 2015-06-30 |
$0.43B |
$0.13B |
31.16% |
| 2015-03-31 |
$0.41B |
$0.12B |
28.99% |
| 2014-12-31 |
$0.40B |
$0.12B |
29.95% |
| 2014-09-30 |
$0.40B |
$0.07B |
16.50% |
| 2014-06-30 |
$0.35B |
$0.05B |
13.96% |
| 2014-03-31 |
$0.32B |
$0.05B |
16.10% |
| 2013-12-31 |
$0.31B |
$0.06B |
19.87% |
| 2013-09-30 |
$0.31B |
$0.06B |
19.74% |
| 2013-06-30 |
$0.29B |
$0.05B |
17.77% |
| 2013-03-31 |
$0.28B |
$0.04B |
15.64% |
| 2012-12-31 |
$0.28B |
$0.04B |
14.89% |
| 2012-09-30 |
$0.30B |
$0.06B |
21.02% |
| 2012-06-30 |
$0.29B |
$0.05B |
18.47% |
| 2012-03-31 |
$0.31B |
$0.06B |
20.98% |
| 2011-12-31 |
$0.27B |
$0.04B |
14.96% |
| 2011-09-30 |
$0.27B |
$0.03B |
11.15% |
| 2011-06-30 |
$0.28B |
$0.05B |
16.90% |
| 2011-03-31 |
$0.26B |
$0.04B |
16.28% |
| 2010-12-31 |
$0.29B |
$0.08B |
27.62% |
| 2010-09-30 |
$0.24B |
$0.05B |
19.83% |
| 2010-06-30 |
$0.21B |
$0.02B |
10.68% |
| 2010-03-31 |
$0.22B |
$0.03B |
13.82% |
| 2009-12-31 |
$0.24B |
$0.05B |
19.15% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.592B |
$1.793B |
|
Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining the trust of their customers, employees and shareholders. The foundation of the corporate governance principles and practices are built on their reputation for openness, integrity and accountability. These are the principles that guide Emergent BioSolutions everyday. They have in place policies and practices to ensure that their Company is managed with integrity and in their shareholders' best interests. In addition, they are committed to meeting the requirements of federal and state law and the rules of the New York Stock Exchange.
|
